key: cord-1020600-qkp5mlwn
authors: Azabou, Eric; Bao, Guillaume; Bounab, Rania; Heming, Nicholas; Annane, Djillali
title: Vagus Nerve Stimulation: A Potential Adjunct Therapy for COVID-19
date: 2021-05-07
journal: Front Med (Lausanne)
DOI: 10.3389/fmed.2021.625836
sha: e0cc2d2a21c7f56c04d97971410bf1a65037255c
doc_id: 1020600
cord_uid: qkp5mlwn

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) through excessive end organ inflammation. Despite improved understanding of the pathophysiology, management, and the great efforts worldwide to produce effective drugs, death rates of COVID-19 patients remain unacceptably high, and effective treatment is unfortunately lacking. Pharmacological strategies aimed at modulating inflammation in COVID-19 are being evaluated worldwide. Several drug therapies targeting this excessive inflammation, such as tocilizumab, an interleukin (IL)-6 inhibitor, corticosteroids, programmed cell death protein (PD)-1/PD-L1 checkpoint inhibition, cytokine-adsorption devices, and intravenous immunoglobulin have been identified as potentially useful and reliable approaches to counteract the cytokine storm. However, little attention is currently paid for non-drug therapeutic strategies targeting inflammatory and immunological processes that may be useful for reducing COVID-19-induced complications and improving patient outcome. Vagus nerve stimulation attenuates inflammation both in experimental models and preliminary data in human. Modulating the activity of cholinergic anti-inflammatory pathways (CAPs) described by the group of KJ Tracey has indeed become an important target of therapeutic research strategies for inflammatory diseases and sepsis. Non-invasive transcutaneous vagal nerve stimulation (t-VNS), as a non-pharmacological adjuvant, may help reduce the burden of COVID-19 and deserve to be investigated. VNS as an adjunct therapy in COVID-19 patients should be investigated in clinical trials. Two clinical trials on this topic are currently underway (NCT04382391 and NCT04368156). The results of these trials will be informative, but additional larger studies are needed.

The coronavirus disease 2019 pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) faced currently worldwide includes in its pathophysiology an excessive inflammatory phase called "cytokine storm" that is closely linked to its high mortality (1, 2) . During sepsis, the host response to a pathogen is mediated by the interaction between pathogen-associated molecular pattern and their receptors located on innate immune cells (3) . This interaction leads to activation of the innate immune cell, release of inflammatory cytokines, and recruitment of further cells of the immune system (4) . When this immune response is exaggerated, excessive inflammation may lead to end tissue damage. All major organs may be affected during sepsis including altered hypothalamicpituitary-adrenal and altered cardiovascular responses (5, 6) . Disruption of the hypothalamic-pituitary-adrenal axis may translate in patients with sepsis into cardiovascular and organ dysfunction and an increase in the risk of death (5, 6) . Impaired heart rate variability and high concentrations of circulating catecholamines and impaired sympathetic modulation are common findings of septic and septic shock patients, reflecting dysfunction of the medullary autonomic centers (7) and suggesting that central autonomic regulatory impairment contributes to circulatory failure (8) (9) (10) . Clinical patterns concordant with these hypotheses have been documented in COVID-19 patients and support the hypothesis of a potential contribution of a dysfunction in autonomic tone to the cytokine release syndrome and related multiorgan damage in COVID-19 (11) (12) (13) (14) (15) (16) (17) .

Specific treatment for COVID-19 is unfortunately lacking (18, 19) . However, given the high mortality rate and economic damage to date, great efforts are being made worldwide to produce successful drugs (20) . Particularly, pharmacological strategies that restore inflammatory control or inhibit cytokine release are being evaluated (21) (22) (23) . Several drug therapies targeting this excessive inflammation, such as tocilizumab, an interleukin (IL)-6 inhibitor, corticosteroids, programmed cell death protein (PD)-1/PD-L1 checkpoint inhibition, cytokine-adsorption devices, and intravenous immunoglobulin have been identified as potentially useful and reliable approaches to counteract cytokine storm in COVID-19 patients (1, 2, 18, (24) (25) (26) (27) (28) (29) (30) (31) (32) . Little attention is currently paid for nondrug therapeutic strategies targeting inflammatory and immunological processes that may be useful for reducing COVID-19-induced complications and improving patient outcome (33) (34) (35) .

Modulating the activity of cholinergic anti-inflammatory pathways (CAPs) described by the group of KJ Tracey (36) (37) (38) (39) (40) (41) (42) (43) (44) has indeed become an important target of therapeutic research strategies for inflammatory diseases and sepsis (37, 38, (45) (46) (47) . In fact, the CAP pathways innervate the spleen through the efferent vagus nerve and the splenic nerve relay and act on macrophages by transforming adrenergic stimulation into a cholinergic signal by the T cells of the spleen, which plays an anti-inflammatory effect (48) .

About 80% of the vagus nerve is composed of afferent sensory fibers carrying information from the periphery to the brain (49) . Within the central nervous system, the vagus primarily projects to the nucleus of the solitary tract (NTS), releasing excitatory neurotransmitters (glutamate and aspartate), inhibitory neurotransmitter (gamma-aminobutyric acid), acetylcholine, norepinephrine, and neuropeptides implicated in signal transduction (49) . In turn, the NTS has widespread efferent pathways to the parabrachial nucleus, reticular formation, basal forebrain, amygdala, hippocampus, hypothalamus, dorsal raphe, cerebellum, and spinal cord (50) . NTS projections to brainstem nuclei (locus coeruleus and dorsal raphe magnus) modulate serotonin and norepinephrine release to the entire brain (51) . Through efferent and afferent fibers, the vagus nerve plays a role in maintaining cardiovascular homeostasis and in modulating inflammation (52) . The autonomic nervous system regulates the production of cytokines, through interactions with the hypothalamic-pituitary-adrenal axis, leading to the release of anti-inflammatory glucocorticoid hormones. Vagal efferent fibers also release acetylcholine (Ach), which, by interacting with α7-subunit-containing nicotinic receptors found in tissue macrophages, and dendritic cells, inhibit the release of proinflammatory cytokines such as tumor necrosis factor alpha (TNFα), IL-1β, IL-6, and IL-18 (36, 53) . Inflammatory reflex signaling, which is enhanced by electrically stimulating the vagus nerve, significantly reduces cytokine production and attenuates disease severity in animal models of inflammatory diseases and in experimental models of sepsis (36, (54) (55) (56) (57) . Electrical stimulation of the vagus nerve attenuates inflammation in a variety of pathological conditions with little side effects (36, 58, 59) . Recently, Meneses and colleagues demonstrated that vagus nerve stimulation attenuates the inflammatory response in the central nervous system induced by peripheral lipopolysaccharide challenge in rats (60) . Kohoutova and colleagues recently demonstrated that vagus nerve stimulation attenuates multiple organ dysfunction in a porcine model of sepsis (61) . These findings suggest that VNS could be a promising adjunctive therapy targeting inflammatory pathways in COVID-19 patients. VNS might attenuate sepsis-related inflammatory processes leading to endothelial activation, impaired microcirculation, multiorgan failure, and death. VNS may also exhibit favorable cardiovascular effects during sepsis, including antiarythmogen, decreased myocardial oxygen consumption, and improved diastole (62) . Vagus nerve stimulation has a favorable safety track record. Implanted VNS devices have been used for decades to treat refractory partial-onset seizures and severe recurrent refractory depression with confirmed safety and only mild to moderate side effects that are predictable improve over time (63) (64) (65) . More recently, non-invasive transcutaneous vagus nerve stimulation devices (t-VNS) have been developed and commercialized (66) . Evidence from preclinical models (61, 67) as well as from several clinical reports (47, 68) is accumulating (68) (69) (70) (71) (72) . Boezaart and Botha reported a drastic reduction of two COVID-19 patients treated with t-VNS (69) . Non-invasive VNS as adjunct therapy in COVID-19 patients might alleviate organ dysfunction and improve patients' outcome. Randomized controlled studies assessing the effectiveness of non-invasive vagus nerve stimulation as adjunct therapy to current best medical practice for COVID-19 are needed (72) . Two studies evaluating the efficacy of non-invasive VNS in COVID-19 patients are now on going using the gammaCore R non-invasive vagal nerve stimulation device. The gammaCore R (electroCore, Inc., Basking Ridge, NJ) is handheld and requires no surgery or implants. The device is applied by healthcare providers or patients to the skin at the neck over the vagus nerve to deliver periodic doses of VNS non-invasively. Tariq Cheema and colleagues are conducting a prospective, randomized, controlled investigation designed to assess the reduction in respiratory distress in a COVID-19 population: the SAVIORII study NCT04382391. The primary objective is to reduce initiation of mechanical ventilation in patients with COVID-19 compared to the control group. Secondary objectives are to evaluate cytokine trends/prevent cytokine storms, evaluate supplemental oxygen requirements, decrease mortality of COVID-19 patients, and delay the onset of mechanical ventilation. The second ongoing clinical trial using the same device is conducted by Carlos Tornero and colleagues NCT04368156: the SAVIOR study. The SAVIOR study is a prospective, randomized, controlled study assessing vagus nerve stimulation in COVID-19 respiratory symptoms (72) . The primary outcome measures were incidence of changes in specific clinical events such as the proportion of subjects requiring mechanical ventilation, days to onset of mechanical ventilation, oxygen support requirements, O 2 saturation, pain levels, PaO 2 /FiO 2 , coagulation, laboratory measurements related to circulating cytokines and inflammation, live discharge from the hospital, patient length of stay, mortality, need for intensive care, shortness of breath, device-related serious adverse events, and adverse events. The results of these trials will be informative, but additional, larger, studies are needed.

COVID-19 remains a major healthcare issue worldwide. Excessive inflammation and its end organ consequences are key elements in the pathogenesis of COVID-19-induced multiple organ dysfunction (19, 26, 32) . Specific treatment for COVID-19 is unfortunately lacking. Several promising pharmacological strategies aimed at modulating inflammation in COVID-19 are being evaluated worldwide. However, little attention is currently paid for non-drug therapeutic strategies targeting inflammatory and immunological processes, which may be useful for reducing COVID-19-induced complications and improving patient outcome (33) (34) (35) . Vagal neurostimulation has a wide field of therapeutic benefit for patients and should be combined with the best current medical strategies (15, 17, 69, 70) . Vagus nerve stimulation attenuates inflammation both in experimental models and preliminary data in man. The development non-invasive vagal nerve stimulation (t-VNS), a non-pharmacological adjuvant, may help reduce the burden of COVID-19 and deserve to be investigated. The aim of this paper is to promote the emergence of original studies assessing noninvasive VNS as an adjuvant treatment for the management of COVID-19.

EA and DA conceived the manuscript. EA, NH, GB, RB, and DA were involved in early discussions and mapping the concepts that led to this paper and wrote the first draft of the manuscript. All authors read and critically reviewed drafts of the manuscript.

Cytokine storm in COVID-19: pathogenesis and overview of antiinflammatory agents used in treatment

Infusion of HLA-matched and static magnetic field-exposed allogenic lymphocytes treating lymphocytopenia and cytokine storm syndrome: a treatment proposal for COVID-19 patients

Role of cytokines and pathogen associated molecular pattern receptors in sepsis

Severe sepsis and septic shock

The role of ACTH and corticosteroids for sepsis and septic shock: an update. Front Endocrinol (Lausanne)

Vasopressin impairment during sepsis is associated with hypothalamic intrinsic apoptotic pathway and microglial activation

Hydrocortisone effects on cardiovascular variability in septic shock: a spectral analysis approach

Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach

Adjunctive treatment in septic shock: what's next?

Design and conduct of the activated protein C and corticosteroids for human septic shock (APROCCHSS) trial. Ann Intensive Care

Autonomic dysfunction heralding acute motor axonal neuropathy in COVID-19

The extended autonomic system, dyshomeostasis, and COVID-19

Is 'happy hypoxia' in COVID-19 a disorder of autonomic interoception? A hypothesis

Testing cardiovascular autonomic function in the COVID-19 era: lessons from Bologna's Autonomic Unit

Autonomic function testing in the COVID-19 pandemic: an American Autonomic Society position statement

Non-epileptic seizures in autonomic dysfunction as the initial symptom of COVID-19

Autonomic brain centers and pathophysiology of COVID-19

Cytokine storm in COVID-19: the current evidence and treatment strategies

Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review

Addition of tocilizumab to the standard of care reduces mortality in severe COVID-19: a systematic review and meta-analysis

Cytokine storm and the prospects for immunotherapy with COVID-19

Three novel prevention, diagnostic, and treatment options for COVID-19 urgently necessitating controlled randomized trials

Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts

Cilastatin: a potential treatment strategy against COVID-19 that may decrease viral replication and protect from the cytokine storm

Successful treatment of acute heart failure in COVID-19-induced cytokine storm with tocilizumab: a case report

Cytokine storm in COVID-19 patients, its impact on organs and potential treatment by QTY code-designed detergent-free chemokine receptors

COVID-19: proposing a ketone-based metabolic therapy as a treatment to blunt the cytokine storm

Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab

Treatment of cytokine storm in COVID-19 patients with immunomodulatory therapy

Treatment of severe COVID-19 with tocilizumab mitigates cytokine storm and averts mechanical ventilation during acute respiratory distress: a case report and literature review

Tocilizumab: a therapeutic option for the treatment of cytokine storm syndrome in COVID-19

Randomized controlled study evaluating efficiency of low intensity transcranial direct current stimulation (tDCS) for dyspnea relief in mechanically ventilated COVID-19 patients in ICU: THe tDCS-DYSP-COVID Protocol

Implications for neuromodulation therapy to control inflammation and related organ dysfunction in COVID-19

Update on the use of transcranial electrical brain stimulation to manage acute and chronic COVID-19 symptoms

Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin

The vagus nerve and the inflammatory reflex: wandering on a new treatment paradigm for systemic inflammation and sepsis

The cholinergic antiinflammatory pathway: a critical review

The inflammatory reflex and the role of complementary and alternative medical therapies

Alpha7 nicotinic acetylcholine receptor (alpha7nAChR) expression in bone marrow-derived non-T cells is required for the inflammatory reflex

Bioelectronic medicine: from preclinical studies on the inflammatory reflex to new approaches in disease diagnosis and treatment. Cold Spring Harb Perspect Med

The vagus nerve and the inflammatory reflexlinking immunity and metabolism

Adenylyl cyclase 6 mediates inhibition of TNF in the inflammatory reflex

The inflammatory reflex

The role of alpha7nAChR-mediated cholinergic anti-inflammatory pathway in immune cells

Activation of cholinergic anti-inflammatory pathway in peripheral immune cells involved in therapeutic actions of alpha-mangostin on collagen-induced arthritis in rats

Cholinergic anti-inflammatory pathway and its role in treatment of sepsis. Zhong Nan Da Xue Xue Bao Yi Xue Ban

Research progress of exploring the treatment of sepsis based on cholinergic anti-inflammatory pathway

Vagus nerve stimulation

Vagus nerve stimulation: indications and limitations

Therapeutic mechanisms of vagus nerve stimulation

Functional and chemical anatomy of the afferent vagal system

Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia

Neural reflexes in inflammation and immunity

Splenectomy inactivates the cholinergic antiinflammatory pathway during lethal endotoxemia and polymicrobial sepsis

Anti-inflammatory effect of vagus nerve stimulation in a rat model of inflammatory bowel disease

Stimulation of nicotinic acetylcholine receptors attenuates collagen-induced arthritis in mice

Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis

Electrical vagus nerve stimulation attenuates systemic inflammation and improves survival in a rat heatstroke model

Electric stimulation of the vagus nerve reduced mouse neuroinflammation induced by lipopolysaccharide

Vagus nerve stimulation attenuates multiple organ dysfunction in resuscitated porcine progressive sepsis

Protective effect of vagal stimulation on reperfusion arrhythmias in cats

Vagus nerve stimulation, side effects, long-term safety

Evidence-based guideline update: vagus nerve stimulation for the treatment of epilepsy: report of the guideline development subcommittee of the american academy of neurology

The long-term effect of vagus nerve stimulation on quality of life in patients with pharmacoresistant focal epilepsy: the PuLsE (Open Prospective Randomized Long-term Effectiveness) trial

Non-invasive access to the vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans

Vagus nerve regulates the phagocytic and secretory activity of resident macrophages in the liver

The use of non-invasive vagus nerve stimulation to treat respiratory symptoms associated with COVID-19: a theoretical hypothesis and early clinical experience

Treatment of stage 3 COVID-19 with transcutaneous auricular vagus nerve stimulation drastically reduces interleukin-6 blood levels: a report on two cases

Targeting the cholinergic antiinflammatory pathway with vagus nerve stimulation in patients with Covid-19?

The use of non-invasive vagus nerve stimulation to treat respiratory symptoms associated with COVID-19: a theoretical hypothesis and early clinical experience

A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore(R)-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): a structured summary of a study protocol for a randomised controlled trial